Company intelligence / Profile preview
PROTEINA Co., Ltd.
- Ownership
- Private
- Development stage
- Other
Overview
PROTEINA has developed a proprietary platform that quantitatively measures protein-protein interactions from clinical samples. This approach enables more precise diagnostics and the identification of novel therapeutic targets. The company is preparing to enter Phase 1 human trials for blood cancer through a collaboration with a major global pharmaceutical company based in Chicago. If successful, this would be the first such trial using PPI technology on humans.
- Therapeutic areas
- Oncology
- Modalities
- Protein-protein interaction (PPI) analysis and diagnosticsPotentially protein-based therapeutics in partnership programs
- Industry
- Protein Biomarker Diagnostics
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on PROTEINA Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PROTEINA Co., Ltd..